Negative prognostic factors in MCL
Clinical feature and genomic aberration . | No. of patients . | All patients evaluable for the characteristic . | % . | P . |
|---|---|---|---|---|
| Clinical feature | ||||
| LDH level elevated | 10 | 31 | 32.3 | < .001 |
| Older than 60 y | 20 | 36 | 55.6 | .093 |
| Stage III/IV | 32 | 35 | 92.5 | .508 |
| 2 or more extranodal sites | 24 | 34 | 70.6 | .057 |
| WHO performance status of 2 or more | 6 | 30 | 20.0 | .169 |
| Genomic alteration | ||||
| 8p21 deletion | 14 | 36 | 38.9 | .033 |
| 13q14 deletion | 19 | 36 | 52.8 | .010 |
Clinical feature and genomic aberration . | No. of patients . | All patients evaluable for the characteristic . | % . | P . |
|---|---|---|---|---|
| Clinical feature | ||||
| LDH level elevated | 10 | 31 | 32.3 | < .001 |
| Older than 60 y | 20 | 36 | 55.6 | .093 |
| Stage III/IV | 32 | 35 | 92.5 | .508 |
| 2 or more extranodal sites | 24 | 34 | 70.6 | .057 |
| WHO performance status of 2 or more | 6 | 30 | 20.0 | .169 |
| Genomic alteration | ||||
| 8p21 deletion | 14 | 36 | 38.9 | .033 |
| 13q14 deletion | 19 | 36 | 52.8 | .010 |